I agree Elite is very likely to grow sales significantly as new products come to market. The stock is a buy. That said, Vyvanse was brand name only for the market size time frame in the press release. My guess is the dollar value of the market will drop by at least 50% after multiple generics are approved. It’s still real money. Elite will win a slice of the pie… but it won’t be a $5 billion dollar market. Just trying to keep it real.
News 
Market Data 
Discover 
